Kazuki Nozawa, MD· @kazuki_nozawa · X·· 2 天前评分70
正文 · 原文
TALENT trial
#ESMO26
Neoadjuvant T-DXd showed modest efficacy (pCR 3–9%), with limited benefit from additional therapy and potential safety concerns.
572 浏览 · 8 赞 · 3 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Kazuki Nozawa, MD · x.com